The Europe CGMS market is estimated to garner $351.7 million by 2021, registering a CAGR of 38.0% during the forecast period. This market is expected to witness significant growth from 2015 to 2021, owing to numerous advantages of CGMS such as minimal invasiveness and real-time blood glucose monitoring. In addition, increasing incidence of diabetes cases in Europe, increasing per capita healthcare expenditure, and growing purchasing power on account of high disposable income of individuals have fueled the market growth. Furthermore, ability of CGMS to provide detailed analysis of blood glucose levels and higher precision as compared to traditional blood glucose monitoring has supplemented the market growth. However, high costs associated with CGMS, lack of adequate reimbursement policies, and limited awareness about CGMS among patients are the major factors hampering the growth of the market.
The report segments the Europe CGMS market on the basis of country and components. Based on country, the market is segmented into the U.K., France, Germany, Norway, Sweden, Denmark, Finland and Other Europe. Presently, the Germany leads the Europe CGMS market, owing to its large diabetes patient pool and high healthcare expenditure. The components of the CGMS comprise sensors, transmitters & receivers, and integrated insulin pumps. The sensors segment dominates the market, as the sensor loses its sensitivity after using if for about 5 to 7 days, which requires frequent requirement.
Europe CGMS market has presence of numerous manufacturers that are adopting partnership and collaboration as their strategy to commercialize CGMS. For instance, Senseonics and Rubin Medical have adopted the collaboration strategy to commercialize their CGMS products in Denmark and Sweden. The companies profiled in the report include Medtronic Inc., Dexcom, Inc., Abbott Diabetic care, Senseonics Incorporated, Insulet Corporation, Echo therapeutics, Glysens Inc. and Animas Corporation.
KEY BENEFITS FOR STAKEHOLDERS:
- This report provides an in-depth analysis of the current and emerging market trends and dynamics in the Europe CGMS market.
- The European CGMS market is analyzed based on countries such as the U.K., France, Germany, Norway, Sweden, Denmark, Finland, and Other Europe.
- An in-depth analysis of key strategies adopted by key manufacturers helps in understanding competitive scenario.
- This report provides an exhaustive analysis of the factors that drive and restrict the growth of the Europe CGMS market.
- The reimbursement scenario of CGMS devices has been provided in this report.
EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET KEY SEGMENTS:
- Other Europe
- Transmitters & receivers
- Integrated insulin pumps
1.1 Market definition and scope
1.2 Research methodology
1.2.1 Secondary research
1.2.2 Primary Research
1.2.3 Analyst Tools and Models
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2021 ($THOUSANDS)
3.1.1 Market size and forecast
CHAPTER 4 U.K. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2021 ($THOUSANDS)
4.1 Key market trends
4.2 Key growth factors and opportunities
4.3 Market size and forecast
4.4 Reimbursement scenario
CHAPTER 5 GERMANY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2021 ($THOUSANDS)
5.1 Key market trends
5.2 Key growth factors and opportunities
5.3 Market size and forecast
5.4 Reimbursement scenario
CHAPTER 6 FRANCE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2021 ($THOUSANDS)
6.1 Key market trends
6.2 Key growth factors and opportunities
6.3 Market size and forecast
6.4 Reimbursement scenario
CHAPTER 7 NORWAY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2021 ($THOUSANDS)
7.1 Key market trends
7.2 Key growth factors and opportunities
7.3 Market size and forecast
7.4 Reimbursement scenario
CHAPTER 8 SWEDEN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2021, ($THOUSANDS)
8.1 Key market trends
8.2 Key growth factors and opportunities
8.3 Market size and forecast
8.4 Reimbursement scenario
CHAPTER 9 DENMARK CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2021, ($THOUSANDS)
9.1 Key market trends
9.2 Key growth factors and opportunities
9.3 Market size and forecast
9.4 Reimbursement scenario
CHAPTER 10 FINLAND CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2021, ($THOUSANDS)
10.1 Key market trends
10.2 Key growth factors and opportunities
10.3 Market size and forecast
10.4 Reimbursement scenario
CHAPTER 11 OTHER EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2021, ($THOUSANDS)
11.1 Key market trends
11.2 Key growth factors and opportunities
11.3 Market Size and Forecast
11.4 Reimbursement Scenario
11.4.2 The Netherlands
CHAPTER 12 COMPANY PROFILES
12.1 Medtronic Inc.
12.1.1 Company overview
12.1.2 Company snapshot
12.1.3 Business performance
12.1.4 Strategic moves and developments
22.214.171.124 Principal strategies: product launch
126.96.36.199 Secondary strategies: approval
188.8.131.52 Other strategies: strategic alliance and collaboration
12.1.5 SWOT analysis of Medtronic Inc.
12.2 Dexcom Inc.
12.2.1 Company overview
12.2.2 Company snapshot
12.2.3 Business performance
12.2.4 Strategic moves and developments
184.108.40.206 Principal strategies: agreement/partnership
220.127.116.11 Secondary strategies: approval
18.104.22.168 Other strategies: acquisition
12.2.5 SWOT analysis of Dexcom
12.3 Abbott Diabetic Care (Abbott Laboratories)
12.3.1 Company overview
12.3.2 Company snapshot
12.3.3 Business performance
12.3.4 Strategic moves and developments
12.3.5 SWOT analysis of Abbott diabetic care
12.4 Senseonics, Incorporated
12.4.1 Company overview
12.4.2 Company snapshot
12.4.3 Strategic moves and development
12.4.4 SWOT analysis of Senseonics
12.5 Animas Corporation
12.5.1 Company overview
12.5.2 Company snapshot
12.5.3 Strategic moves and developments
12.5.4 SWOT analysis of Animas Corporation
12.6 Insulet Corporation
12.6.1 Company overview
12.6.2 Company snapshot
12.6.3 Strategic moves and developments
12.6.4 SWOT analysis of INSULET Corporation
12.7 Echo Therapeutics
12.7.1 Company Overview
12.7.2 Company snapshot
12.7.3 Strategic moves and development
12.7.4 SWOT analysis of Echo Therapeutics
12.8 Glysens Inc.
12.8.1 Company overview
12.8.2 Company snapshot
12.8.3 Strategic moves and developments
12.8.4 SWOT analysis of Glysens Inc.
List of Tables
Table 1 Europe CGMs Market By Country, 2014-2021, ($Thousands)
Table 2 U.K. CGMs Market By Components, 2014-2021, ($Thousands)
Table 3 Germany CGMs Market By Components, 2014-2021, ($Thousands)
Table 4 France CGMs Market By Components, 2014-2021, ($Thousands)
Table 5 Norway CGMs Market By Components, 2014-2021, ($Thousands)
Table 6 Sweden CGMs Market By Components, 2014-2021, ($Thousands)
Table 7 Denmark CGMs Market By Components, 2014-2021 ($Thousands)
Table 8 Finland CGMs Market By Components, 2014-2021, ($Thousands)
Table 9 Other Europe CGMs Market By Components, 2014-2021, ($Thousands)
Table 10 Medtronic Business Snapshot
Table 11 Dexcom Inc. Business Snapshot
Table 12 Abbott Diabetic Carebusiness Snapshot
Table 13 Senseonics Snapshot
Table 14 Animas Corporation Business Snapshot
Table 15 Insulet Corporation Business Snapshot
Table 16 Glysens Inc. Business Snapshot
List of Figures
Fig. 1 Medtronic Revenue By Business Units (2014)
Fig. 2 Medtronic Revenue By Geography (2014)
Fig. 3 Swot Analysis Of Medtronic
Fig. 4 Swot Analysis Of Dexcom Inc.
Fig. 5 Revenue By Business Segment (2014)
Fig. 6 Swot Analysis Of Abbott Diabetic Care
Fig. 7 Swot Analysis Of Senseonics
Fig. 8 Swot Analysis Of Animas Corporation
Fig. 9 Swot Analysis Of Insulet Corporation
Fig. 10 Swot Analysis Of Echo Therapeutics
Fig. 11 Swot Analysis Of Glysen Incorporated
The European CGMS market is expected to witness dynamic growth, owing to increasing incidence rates of diabetes, growing per capita healthcare expenditure, and rising disposable income of individuals. In addition, CGMS offers various benefits over conventional glucose monitors such as higher precision, greater sensitivity, and periodic monitoring. CGMS technology is applicable in “artificial/bionic pancreas”; hence, several CGMS and insulin pump manufacturers focus on the development of novel and advanced CGMS. CGMS can be used across all age groups and various healthcare settings. However, unfavorable reimbursement policies for CGMS is expected to hamper the market growth.
Glucose sensors is expected to dominate the European CGMS component market during the forecast period due to CE approval on CGMS sensors and supportive reimbursement policies. Moreover, technological advancements in this sector have led to the development of sensor-augmented pumps that can be linked with CGMS devices for real-time monitoring using various wireless monitoring systems such as smartphones.
Germany is the leading revenue-generating country, owing to favorable guidelines about pricing and fixed reimbursement budget allocation for CGMs devices. In addition, the European CGMS market is estimated to exhibit significant growth in Norway, Sweden, and Denmark due to advanced diabetes care facilities and robust clinical guidelines and standards for diabetes management.
Key findings of the study:
- U.K. is projected to grow at the highest CAGR of 40.9% during the forecast period.
- Germany generated one-fourth of the total market revenue in 2015 and is projected to be the maximum revenue generating country till 2021.
- Sensors segment accounted for about two third of the market revenue in 2015 and is projected to exhibit prominent growth during the forecast period.
- U.K., Germany and France contributed over half of the market share in 2015.
Renowned companies, such as Senseonics and Rubin Medical, have adopted the collaboration strategy to commercialize their CGMS products in Denmark and Sweden. Increasing number of diabetic patients, well-structured diabetes management regime, and proactive initiatives taken by the government have encouraged several CGMS companies to invest in Europe. Medtronic Inc., Dexcom, Inc., Abbott Diabetic care, Senseonics Incorporated, Insulet Corporation, Echo therapeutics, Glysens Inc. and Animas Corporation are some of the prominent players in the European CGMS market.